Key Highlights
● Firefly Neuroscience (AIFF) closed at $1.69 on Monday, down 15.92% from $2.01, giving back part of Friday's surge.
● Firefly announced on September 25 a Partnership with NeuroSigma to widen clinician access to the Monarch eTNS pediatric ADHD device.
● The partnership announcement disclosed no financial terms, and no new company news dated Monday was found to explain the decline.
● The Nasdaq Composite fell 248.34 points to 26,820.38 as the 10-year Treasury Yield reached its highest since 2007.
Firefly Neuroscience (NASDAQ:AIFF) gave back part of its Friday surge on Monday, September 28. The stock closed at $1.69, down 15.92% from $2.01 in the previous session. The company builds AI-based tools for analysing brain activity, and its shares had jumped on Friday after it announced a partnership with NeuroSigma.
What the Partnership Covers
According to the September 25 announcement, Firefly will introduce NeuroSigma's Monarch eTNS System to its Evoke network of clinicians and support their education. Monarch is a palm-sized device that delivers mild external trigeminal nerve stimulation through a forehead patch worn during sleep. It is cleared by the US Food and Drug Administration as a non-drug treatment for children aged 7 to 12 with attention-deficit/hyperactivity disorder who are not taking prescription medication.
NeuroSigma is to provide clinical training, prescribing support and product fulfillment. No financial terms were disclosed. Firefly describes its own platform as an AI-powered diagnostic system built on a database of more than 200,000 brain scans. The announcement added that NeuroSigma began US sales of a second-generation Monarch device in July 2026 and widened payment Options for families in September.
Why Sharp Gains Can Retrace
No new company announcement dated Monday was found, so this article does not link the decline to any specific development. In general, a stock that jumps on a headline can lose part of the move as short-term holders take profits, and partnerships without disclosed terms leave investors to judge the potential value for themselves. Across the market, small caps lagged. The Russell 2000 fell 19.64 points, and lows swamped highs on the Nasdaq, 461 to 50.
A Weak Tape for Speculative Names
Stocks finished the day lower: the S&P 500 sank 59.72 points to 7,683.69, the Dow slid 347.11 points to 51,481.51, and the Nasdaq Composite lost 248.34 points to 26,820.38.
Government bonds sold off hard, sending the 10-year Treasury yield to its highest since 2007 and the 30-year to its highest since 2004, a squeeze that hits stocks priced on distant profits. Geopolitics fed the rate story: after President Trump rejected Iran's proposal on the Strait of Hormuz, oil moved higher, with West Texas Intermediate near $92.60 a barrel.
Young companies with small market values are often the first to feel a shift in risk appetite, because investors can reduce exposure to them quickly when conditions turn. Friday's close of $2.01 is the reference point for Monday's decline.
What to Watch for Firefly Neuroscience
Investors will look for further detail from Firefly on how the NeuroSigma arrangement works in practice, including how many clinicians in its network take up the device and when any Revenue might follow. Company press releases and filings with the Securities and Exchange Commission are where such an update would appear.
Investors will parse a full slate of data this week: JOLTS and consumer confidence on Tuesday, PCE Inflation on Wednesday, ISM Manufacturing on Thursday and the September jobs report on Friday. After the Federal Reserve's September 16 rate increase to a 3.75% to 4.00% range, futures point to a better-than-even chance of another hike in October.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...